Sutent, which is cleared for gastrointestinal stromal tumours (GIST) and kidney cancer and generated $847m (€600m) in global sales last year alone, has had a mixed 2009.
In March Pfizer stopped a Phase III of Sutent in a relatively form of pancreatic cancer trial ahead of schedule after the drug provided patients with ”significant benefits” over comparator therapies.
The following month, a late-stage study in breast cancer was abandoned after Sutent failed to demonstrate superiority as a standalone treatment to Xeloda (capecitabine) made by Swiss rival Roche.
